On Friday, Following Biotechnology Stocks were among the “Top Gainers” In U.S. Stock Exchange: Great Basin Scientific (NASDAQ:GBSN), Conatus Pharmaceuticals (NASDAQ:CNAT), Intrexon (NYSE:XON), Juno Therapeutics (NASDAQ:JUNO), Incyte (NASDAQ:INCY)
Great Basin Scientific Inc (NASDAQ:GBSN) enhanced 40.72%, and closed at $2.73. The company holds the market capitalization of $9.92M. For the last twelve months, the stock was able to keep return on equity at 63.60%, while return on assets at -361.50%, in response to its return on investment at 277.30%. Its 20-day moving average gained 19.29%, below 50-day moving average of 27.42%, above 200-day moving average of -12.91% from the latest market price of $2.73.
Great Basin Scientific Inc (NASDAQ:GBSN) a molecular diagnostics company, develops and manufactures test kits and analyzers for a patented molecular diagnostic system used in single pathogen tests.
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) promulgated top-line results from the company’s Phase 2 double-blind, placebo-controlled clinical trial of emricasan, a first-in-class, verbally active pan-caspase protease inhibitor, in 38 patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with nonalcoholic steatohepatitis (NASH). The trial met its primary endpoint, showing a statistically significant (p<0.05) reduction in alanine amino transferase (ALT) in patients treated for 28 days with emricasan at 25 mg twice per day dosing compared to patients in the placebo control group. Reductions from baseline in ALT at Day 28 of approximately 39% in the emricasan treatment arm and approximately 14% in the placebo arm were similar to results observed in previous trials. Elevated baseline levels of three key serum biomarkers — caspase-cleaved cytokeratin 18 (cCK18), full length cytokeratin 18, and caspase 3/7 — also showed statistically significant reductions from baseline in emricasan-treated patients at Day 28. The baseline elevation in cCK18 confirmed that the underlying targets of emricasan’s mechanism, apoptosis and inflammation, which are believed to drive liver disease progression, were engaged in the NAFLD/NASH patients in this trial.
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) inclined 14.64%, and closed at $7.75. The company has the market capitalization of $106.09 million. On the other hand the stock’s volatility for the week is 12.79%, and for the month is 7.86%. The stock’s price to book ratio is $3.64. Analyst’s mean recommendation regarding this stock is 2.00. (Where 1=Buy, 5=Sale).
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease.
Intrexon Corp (NYSE:XON) a leader in synthetic biology, uncovered it has entered into a definitive contract to acquire ActoGeniX, a European clinical stage biopharmaceutical company forging a new frontier in cellular therapeutics. The proprietary TopAct™ platform developed by ActoGeniX enables the molecular engineering of food-grade microbes (Lactococcus lactis) to generate biologically-contained ActoBiotics™ for in situ expression and secretion of novel biotherapeutic proteins and peptides including cytokines, enzymes, hormones, and monoclonal antibodies to the oral and gastrointestinal tract. This groundbreaking class of orally available biopharmaceuticals has the potential to facilitate targeted therapies against oral, gastrointestinal, metabolic, allergic and autoimmune diseases.
Intrexon Corp (NYSE:XON) rose 9.22%, and closed at $43.00.its volatility for the week is 8.21%, while for the month it is 6.85%. The company has the market capitalization of $4.51 billion. The company holds the book value per share of 3.83, whereas cash per share is 1.10. Price to book ratio remained 11.23, while price to sale ratio is 62.78. Analysts mean recommendation for the stock is said to be 2.00 (where 1=Buy, 5=sale).
Intrexon Corp (NYSE:XON) a biotechnology company, works in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components.
Formerly On March 18, 2015 Juno Therapeutics Inc (NASDAQ:JUNO) a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, disclosed business highlights and financial results for the fourth quarter and year ended December 31, 2014.
CD19-Directed Product Candidates
At the 56th annual American Society of Hematology (ASH) meeting:
JCAR015 data presentation demonstrated an 89% complete remission (CR) rate in 27 evaluable relapsed/refractory (r/r) adult acute lymphoblastic leukemia (ALL) patients
JCAR017 data presentation demonstrated an 85% CR rate in 13 r/r evaluable pediatric ALL patients
JCAR014 data presentations demonstrated a 100% CR rate in 11 evaluable r/r adult ALL patients and a 60% overall response rate in 10 evaluable r/r non-Hodgkin’s lymphoma patients
Juno Therapeutics Inc (NASDAQ:JUNO)’s shares picked up 5.93%, and closed at $56.60. The stock volatility for the week is 8.35%, while for the month remained 7.65%. The company holds consensus target price of $63.75.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -2.24 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 77.30%.
The mean recommendation of analysts for this stock is 2.30. (Where 1=Buy, 5=Sale).
Juno Therapeutics Inc (NASDAQ:JUNO) a biopharmaceutical company, involves in developing cell-based cancer immunotherapies. The company expands cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
Incyte Corporation (NASDAQ:INCY) uncovered that Novartis received approval from the European Commission for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Under the Incyte-Novartis Collaboration and License contract signed in 2009, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications, and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi® (ruxolitinib). Jakafi® is approved by the U.S. Food and Drug Administration for treatment of people with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
Incyte Corporation (NASDAQ:INCY) enhanced 5.78%, and closed at $94.36. The company holds the market capitalization of $16.21B. For the last twelve months, the stock was able to keep return on equity at 65.30%, while return on assets at -11.10%, in response to its return on investment at -0.80%. Its 20-day moving average gained 3.98%, below 50-day moving average of 13.04%, below 200-day moving average of 45.99% from the latest market price of $96.34. The mean recommendation of analysts for this stock is 1.60. (Where 1=Buy, 5=Sale).
Incyte Corporation (NASDAQ:INCY) a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
